SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-050013
Filing Date
2021-10-04
Accepted
2021-10-04 16:00:39
Documents
12
Period of Report
2021-10-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sndx-8k_20211004.htm   iXBRL 8-K 34397
  Complete submission text file 0001564590-21-050013.txt   170301

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sndx-20211004.xsd EX-101.SCH 5677
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE sndx-20211004_lab.xml EX-101.LAB 20826
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sndx-20211004_pre.xml EX-101.PRE 12379
5 EXTRACTED XBRL INSTANCE DOCUMENT sndx-8k_20211004_htm.xml XML 3788
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

IRS No.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 211302593
SIC: 2834 Pharmaceutical Preparations